Key Highlights

  • Group Revenue was $245 million, up 19 per cent from $206 million a year earlier.
  • Precision Medicine revenue rose 30% to $201 million, mainly from Illuccix and Gozellix.
  • TMS revenue was $44 million, down 6 per cent from $47 million.
  • Telix agreed to acquire ITM for $1.65 billion upfront, with a Shareholder vote expected on 1 December 2026.

How does a radiopharmaceutical company fund an expensive clinical pipeline while still growing revenue? Telix Pharmaceuticals Limited (ASX:TLX) is attempting it through prostate cancer imaging kits that already sell in volume, and the latest evidence is its September 2026 quarter. Group revenue was reported at $245 million, up 19% on $206 million a year earlier, and the company has announced an agreement to buy Isotope Technologies Munich (ITM) for $1.65 billion upfront. The quarter and the deal together show a Business that is commercial and capital-hungry at the same time.

Currency note: Telix reports in US dollars.

What Telix sells

Telix develops and sells products that use radioactive isotopes to image and treat cancer. Its commercial revenue is dominated by Precision Medicine, which includes the PSMA-PET imaging kits Illuccix and Gozellix, used to detect prostate cancer. A second stream, Telix Manufacturing Solutions (TMS), includes radiopharmacy and isotope Supply operations such as RLS Radiopharmacies.

The September 2026 quarter

Precision Medicine revenue was $201 million, up 30% from $155 million, mainly from Illuccix and Gozellix. TMS revenue was $44 million, down 6% from $47 million. Total revenue of $245 million was slightly below the $247 million reported for the June quarter, when Precision Medicine was $202 million and TMS $45 million, so growth was encouraging year on year but flat sequentially. One quarter does not establish a trend, and the pause is a reminder that growth in kit sales does not follow a straight line.

In the June quarter, the company said US dose volumes rose 7%, and revenue was tracking to the upper end of its FY26 guidance. It expected revenue and other income above US$1 billion for the year, including a US$40 million non-refundable payment related to a Regeneron collaboration. For context, the company's FY25 revenue was reported as about US$804 million.

Regulatory milestones

The US Food and Drug Administration approved Pixclara (F-18 floretyrosine), an imaging agent for glioma, with first commercial doses administered in September. A resubmitted application had a target decision date of 11 September 2026, so the approval follows that schedule. Pixclara adds a neuro-oncology imaging product, broadening the portfolio beyond prostate.

Zircaix, a kidney cancer imaging candidate, is more uncertain. As at the June quarter, the company said a Biologics licence application resubmission was nearing completion of final chemistry, manufacturing and controls documentation. Regulatory timing is a persistent risk for the company, since earlier submissions have required resubmission, and approval is never guaranteed.

On the therapeutic side, the company reported that the FDA had allowed the global Phase 3 ProstACT study of TLX591 to advance to Part 2 in the US, that a pivotal trial of TLX250 had dosed its first patient, and that initial cohorts were enrolled in a pivotal glioblastoma trial for TLX101. These are trials, and the outcomes are unknown.

The ITM acquisition

Telix has agreed to acquire ITM, a Munich-based isotope and radiopharmaceutical company, for $1.65 billion upfront, with a shareholder vote expected on 1 December 2026. Strategically, acquiring an isotope producer would give Telix more control over supply of a key input, which matters in a field where isotope availability can limit growth. It would also add integration work and cost.

Financing is also a consideration. In the June quarter, the company said it had issued US$600 million of convertible bonds due 2031 and repurchased its 2029 bonds. Convertible Debt can be cheaper than straight debt but can dilute shareholders if converted.

Competitive position

Radioligand therapy has attracted large pharmaceutical groups, with Novartis the most visible through its prostate cancer therapy, and PSMA imaging faces competition from other approved agents. Telix argues that kit-based products distributed through existing radiopharmacy networks give it flexibility, and that its pipeline spans several tumour types. The competitive question is whether Illuccix and Gozellix can retain share as rival tracers and reimbursement terms change, and whether the pivotal trials can deliver therapies that justify the cost of development.

The company has also established a collaboration with Regeneron on next-generation radiopharmaceutical therapies, and it has been expanding manufacturing, with a new TMS Facility in North Melbourne, a first GMP production run at TMS Brussels South and an ARTMS QUANTM irradiation system at Yokohama. Manufacturing expansion supports supply but also adds fixed costs.

Risks and what to monitor

The principal risks are regulatory outcomes, clinical trial results, reimbursement and pricing for imaging agents, competition, and the ability to integrate a large Acquisition while funding the pipeline. Concentration is another risk: a large share of revenue comes from two prostate imaging products.

Dates to watch are the 1 December shareholder vote on ITM, any announcement on Zircaix, the FY26 full-year results and FY27 guidance, and updates from the pivotal studies.